id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-254469-7q6xi2xx	Wang, Fuzhou	An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development	2020-05-05		.txt	text/plain	4737	245	48	In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US). However, on March 16 2020, the first phase I clinical trial of a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine, mRNA-1273, which encodes the spike protein (S protein) of SARS-CoV-2, began in the United States (US), conducted by Moderna and the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) [12, 13] . Although mRNA vaccines are commencing human clinical trials, due to the rapid global spread of this new viral pandemic, it may not be possible to develop a safe and effective vaccine for SARS-CoV-2 in time to prevent the increasing number of deaths due to this novel RNA virus.	./cache/cord-254469-7q6xi2xx.txt	./txt/cord-254469-7q6xi2xx.txt